BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 15547180)

  • 1. Clinically relevant pneumonitis after sequential paclitaxel-based chemotherapy and radiotherapy in breast cancer patients.
    Yu TK; Whitman GJ; Thames HD; Buzdar AU; Strom EA; Perkins GH; Schechter NR; McNeese MD; Kau SW; Thomas ES; Hortobagyi GN; Buchholz TA
    J Natl Cancer Inst; 2004 Nov; 96(22):1676-81. PubMed ID: 15547180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial.
    Buzdar AU; Singletary SE; Valero V; Booser DJ; Ibrahim NK; Rahman Z; Theriault RL; Walters R; Rivera E; Smith TL; Holmes FA; Hoy E; Frye DK; Manuel N; Kau SW; McNeese MD; Strom E; Thomas E; Hunt K; Ames F; Berry D; Hortobagyi GN
    Clin Cancer Res; 2002 May; 8(5):1073-9. PubMed ID: 12006521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase III trial of sequential adjuvant chemotherapy for operable breast carcinoma: final analysis with 10-year follow-up.
    Assikis V; Buzdar A; Yang Y; Smith T; Theriault R; Booser D; Valero V; Walters R; Singletary E; Ames F; Hortobagyi G
    Cancer; 2003 Jun; 97(11):2716-23. PubMed ID: 12767083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Doxorubicin followed by sequential paclitaxel and cyclophosphamide versus concurrent paclitaxel and cyclophosphamide: 5-year results of a phase II randomized trial of adjuvant dose-dense chemotherapy for women with node-positive breast carcinoma.
    Fornier MN; Seidman AD; Theodoulou M; Moynahan ME; Currie V; Moasser M; Sklarin N; Gilewski T; D'Andrea G; Salvaggio R; Panageas KS; Norton L; Hudis C
    Clin Cancer Res; 2001 Dec; 7(12):3934-41. PubMed ID: 11751485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective randomized trial of paclitaxel alone versus 5-fluorouracil/doxorubicin/cyclophosphamide as induction therapy in patients with operable breast cancer.
    Buzdar AU; Hortobagyi GN; Asmar L; Theriault RL; Rahman Z; McNeese M; Singletary S; Ames F
    Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-31-S17-34. PubMed ID: 9374089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical study of comparison of CAF regimen and TP regimen in treatment of advanced breast cancer].
    Lin XG; Xie DR; Yao HR; Li ZH; Jiang ZM; Liu TH
    Ai Zheng; 2003 Apr; 22(4):411-4. PubMed ID: 12704001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breast-conserving therapy with adjuvant paclitaxel and radiation therapy: feasibility of concurrent treatment.
    Ellerbroek N; Martino S; Mautner B; Tao ML; Rose C; Botnick L
    Breast J; 2003; 9(2):74-8. PubMed ID: 12603378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors for pneumonitis during locoregional radiotherapy in high-risk patients with breast carcinoma treated with high-dose chemotherapy and stem-cell rescue.
    Lind PA; Marks LB; Jamieson TA; Carter DL; Vredenburgh JJ; Folz RJ; Prosnitz LR
    Cancer; 2002 Jun; 94(11):2821-9. PubMed ID: 12115368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Doxorubicin and paclitaxel vs. 5-fluorouracyl, doxorubicin and cyclophosphamid in the first line treatment of metastatic breast cancer].
    Nagykálnai T
    Magy Onkol; 2002; 46(2):192-3. PubMed ID: 12202899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prognostication of hematotoxicity for radio- and chemotherapy in patients with breast cancer].
    Ivanov SD; Iamshanov VA; Korytova LI; Khazova TV; Arzumanov AS
    Vopr Onkol; 2003; 49(5):601-7. PubMed ID: 14682132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment-related leukemia in breast cancer patients treated with fluorouracil-doxorubicin-cyclophosphamide combination adjuvant chemotherapy: the University of Texas M.D. Anderson Cancer Center experience.
    Diamandidou E; Buzdar AU; Smith TL; Frye D; Witjaksono M; Hortobagyi GN
    J Clin Oncol; 1996 Oct; 14(10):2722-30. PubMed ID: 8874333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer.
    Buzdar AU; Singletary SE; Theriault RL; Booser DJ; Valero V; Ibrahim N; Smith TL; Asmar L; Frye D; Manuel N; Kau SW; McNeese M; Strom E; Hunt K; Ames F; Hortobagyi GN
    J Clin Oncol; 1999 Nov; 17(11):3412-7. PubMed ID: 10550135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of pneumonitis in breast cancer patients treated with radiation therapy and combination chemotherapy with paclitaxel.
    Taghian AG; Assaad SI; Niemierko A; Kuter I; Younger J; Schoenthaler R; Roche M; Powell SN
    J Natl Cancer Inst; 2001 Dec; 93(23):1806-11. PubMed ID: 11734597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simultaneous adjuvant radiation therapy and chemotherapy in high-risk breast cancer--toxicity and dose modification: a Transtasman Radiation Oncology Group Multi-Institution study.
    Denham JW; Hamilton CS; Christie D; O'Brien M; Bonaventura A; Stewart JF; Ackland SP; Lamb DS; Spry NA; Dady P
    Int J Radiat Oncol Biol Phys; 1995 Jan; 31(2):305-13. PubMed ID: 7836084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response of disseminated breast cancer to combined modality treatment with chemotherapy and levamisole with or without Bacillus Calmette-Guérin.
    Hortobagyi GN; Yap HY; Blumenschein GR; Gutterman JU; Buzdar AU; Tashima CK; Hersh EM
    Cancer Treat Rep; 1978 Nov; 62(11):1685-92. PubMed ID: 728894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cardiac tolerance of the combination paclitaxel-anthracyclines in the context of the management of cancer of the breast].
    Ferrero JM; Magné N; Foa C; Largillier R; Namer M
    Bull Cancer; 2003 Mar; 90(3):219-26. PubMed ID: 12801824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dexrazoxane cardioprotection for patients receiving FAC chemotherapy: a pharmacoeconomic evaluation.
    Tonkin K; Bates M; Lieu D; Arundell E; Williamson T; Zagari M
    Can J Oncol; 1996 Nov; 6(2):458-73. PubMed ID: 12056098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluorouracil, doxorubicin, and cyclophosphamide versus fluorouracil, doxorubicin, and cyclophosphamide plus lonidamine for the treatment of advanced breast cancer: a multicentric randomized clinical study.
    Calabresi F; Di Lauro L; Marolla P; Curcio CG; Paoletti G; Calabró A; Giannarelli D; Ballatore P; Foggi CM; Di Palma M
    Semin Oncol; 1991 Apr; 18(2 Suppl 4):66-72. PubMed ID: 2031201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy.
    Swain SM; Whaley FS; Gerber MC; Ewer MS; Bianchine JR; Gams RA
    J Clin Oncol; 1997 Apr; 15(4):1333-40. PubMed ID: 9193324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and tolerance of a scalp-cooling system for prevention of hair loss and the experience of breast cancer patients treated by adjuvant chemotherapy.
    Protière C; Evans K; Camerlo J; d'Ingrado MP; Macquart-Moulin G; Viens P; Maraninchi D; Genre D
    Support Care Cancer; 2002 Oct; 10(7):529-37. PubMed ID: 12324807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.